LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Valuation Check After Recent Share Price Weakness And Pipeline Growth Expectations
Recent performance snapshot and context for AstraZeneca
AstraZeneca (LSE:AZN) has come under pressure recently, with the stock down 5.7% over the past week, 2.2% over the past month, and 10.6% over the past 3 months, despite a positive 1 year total return of 24.8%.
At a last close of £132.10 and a market value of about £204.9b, the company reports annual revenue of $60.4b and net income of $10.4b, alongside a value score of 4 and an indicated intrinsic discount of 44.6%.
See our latest...